RxDoctor Payments Data

George Despines, MD

Internal Medicine · Whitman, MANPI 1811970759

Payments from drug & device makers

$386in general payments, 2019–2025

Across 23 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$66
  • Johnson & Johnson$58
  • Pfizer$49
  • Merck$45
  • Astellas Pharma US Inc$34
  • GSK$33
  • plus $100 from 5 others

What the payments were for

  • Food & beverage$386100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$386 in reported general payments places this provider in the 75th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$191,833
Medicare patients
424
Services billed
2,522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban198$170,696
JardianceEmpagliflozin52$53,522
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$47,706
OzempicSemaglutide47$42,366
JanuviaSitagliptin Phosphate31$37,881
XareltoRivaroxaban29$28,121
MyrbetriqMirabegron20$19,429
TradjentaLinagliptin26$16,389
Combivent RespimatIpratropium/Albuterol Sulfate13$14,734
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$12,682
TrulicityDulaglutide12$10,392
Atorvastatin Calcium732$10,148
ShingrixVaricella-Zoster Ge/As01b/Pf46$9,607
Breo ElliptaFluticasone/Vilanterol17$9,443
Atrovent HfaIpratropium Bromide15$8,905

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$49$174,028209 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Incruse Ellipta, Anoro Ellipta$33$82,397156 claims
MerckJanuvia$45$37,88131 claims
Johnson & JohnsonXarelto$58$28,12129 claims
Astellas Pharma US IncMyrbetriq$34$19,42920 claims
AbbVieSynthroid$66$3,73156 claims
Sanofi-aventis U.S. LLCLantus$19$2,25223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Whitman

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →